This event has finished
The BTS webinar "Innovative therapies of EBV-associated PTLD" will be organized as a Zoom meeting on Mar 23, 2021 06:00 PM Brussels time.
Participants can register for free under the following link.
- Introduction and presentation of the speakers by the BTS president (5 minutes)
- Overview of PTLD with a focus on EBV-associated post-transplant PTLD and review of the available therapies (Pr. Daan Dierickx; Hematology Department UZ Leuven) (20 minutes)
- MHC restricted antigen-specific T cell lines developed by Atara Biotherapeutics with focus on mechanism of action and therapeutic use. (Willis Navarro MD; VP of Clinical Research and Development; Atara Biotherapeutics) (20 minutes)
- Innovative anti-EBV T cell therapies (tabelecleucel) as therapy for Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease. Presentation of the ALLELE study (Prof. Sophie Servais; Hematology Department CHU Liège) (20 minutes)
- Questions and answers (15 minutes)
Short biography of the speakers:
Prof Dr. Daan Dierickx is working as a hematologist in the Department of Hematology at the University Hospitals Leuven. His main clinical areas of interest include rare aggressive lymphoproliferative disorders, immune mediated hematological disorders and apheresis. He is also head of the Laboratory of Experimental Hematology at the Catholic University Leuven, where he mainly focuses on unraveling the pathogenic mechanisms of rare lymphoproliferative disorders (in particular posttransplant lymphomas), aiming to identify new potential therapeutic targets.
Prof Dr. Sophie Servais is currently working as clinical hematologist (transplantation and cell therapy department) at the CHU of Liège and as post-doctoral Researcher of the Belgian Foundation against Cancer at the University of Liege. Her work is dedicated to allogeneic stem cell transplantation, and more specifically on the impact of graft source and graft composition on outcomes after stem cell transplantation. Additional fields of interest are immune reconstitution and graft-versus-host disease after allogeneic stem cell transplantation as well as novel cell therapies (such as CAR T cells).